{"id":"paclitaxel-lipid-suspension","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Mucositis"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Alopecia"},{"rate":"10-30%","effect":"Arthralgia"}]},"_chembl":{"chemblId":"CHEMBL3354642","moleculeType":"Small molecule","molecularWeight":"1826.45"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Paclitaxel binds to tubulin, a protein that makes up microtubules, and prevents them from disassembling. This leads to the formation of stable microtubules that prevent cell division, ultimately causing cell death. This mechanism is particularly effective against rapidly dividing cancer cells.","oneSentence":"Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from multiplying.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:25:18.601Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of node-positive breast cancer"},{"name":"Adjuvant treatment of ovarian cancer"},{"name":"Adjuvant treatment of non-small cell lung cancer"},{"name":"Treatment of AIDS-related Kaposi's sarcoma"}]},"trialDetails":[{"nctId":"NCT06867562","phase":"PHASE3","title":"Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jina Pharmaceuticals Inc.","startDate":"2025-04","conditions":"Platinum-Resistant Primary Peritoneal Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer, Platinum Resistant High Grade Serous Ovarian Cancer","enrollment":166}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Paclitaxel Lipid Suspension","genericName":"Paclitaxel Lipid Suspension","companyName":"Jina Pharmaceuticals Inc.","companyId":"jina-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from multiplying. Used for Adjuvant treatment of node-positive breast cancer, Adjuvant treatment of ovarian cancer, Adjuvant treatment of non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}